- Home
- SPXX vs PRQR Comparison
SPXX vs PRQR Comparison
Compare SPXX & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPXX
- PRQR
- Stock Information
- Founded
- SPXX 2004
- PRQR 2012
- Country
- SPXX United States
- PRQR Netherlands
- Employees
- SPXX N/A
- PRQR N/A
- Industry
- SPXX Trusts Except Educational Religious and Charitable
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- SPXX Finance
- PRQR Health Care
- Exchange
- SPXX Nasdaq
- PRQR Nasdaq
- Market Cap
- SPXX 302.8M
- PRQR 309.5M
- IPO Year
- SPXX N/A
- PRQR 2014
- Fundamental
- Price
- SPXX $17.70
- PRQR $3.67
- Analyst Decision
- SPXX
- PRQR Strong Buy
- Analyst Count
- SPXX 0
- PRQR 4
- Target Price
- SPXX N/A
- PRQR $7.13
- AVG Volume (30 Days)
- SPXX 51.3K
- PRQR 534.3K
- Earning Date
- SPXX 01-01-0001
- PRQR 11-07-2024
- Dividend Yield
- SPXX 7.55%
- PRQR N/A
- EPS Growth
- SPXX N/A
- PRQR N/A
- EPS
- SPXX N/A
- PRQR N/A
- Revenue
- SPXX N/A
- PRQR $20,506,357.00
- Revenue This Year
- SPXX N/A
- PRQR $370.31
- Revenue Next Year
- SPXX N/A
- PRQR N/A
- P/E Ratio
- SPXX N/A
- PRQR N/A
- Revenue Growth
- SPXX N/A
- PRQR 306.68
- 52 Week Low
- SPXX $13.57
- PRQR $1.61
- 52 Week High
- SPXX $16.05
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- SPXX 73.41
- PRQR 54.05
- Support Level
- SPXX $17.37
- PRQR $3.37
- Resistance Level
- SPXX $17.78
- PRQR $3.97
- Average True Range (ATR)
- SPXX 0.19
- PRQR 0.21
- MACD
- SPXX 0.03
- PRQR -0.05
- Stochastic Oscillator
- SPXX 89.61
- PRQR 35.71
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio (with a 55% long-term target) in an effort to enhance the Fund's risk-adjusted returns.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.